Involvement of the Mismatch Repair System in Temozolomide-Induced Apoptosis
- 1 August 1998
- journal article
- Published by Elsevier in Molecular Pharmacology
- Vol. 54 (2) , 334-341
- https://doi.org/10.1124/mol.54.2.334
Abstract
Postreplicative mismatch repair plays a major role in mediating the cytotoxicity of agents generatingO6-methylguanine in DNA. We previously showed that a methylating antitumor triazene compound, temozolomide, induces apoptosis and that the persistence ofO6-methylguanine in DNA is required to trigger the process. We wanted to test whether the latter apoptotic signal is dependent on a functional mismatch repair system. To this end, we used two human lymphoblastoid cell lines (i.e., the mismatch repair-proficient TK6 line and its mismatch repair-deficient subline MT1) that are both deficient inO6-methylguanine repair. Temozolomide treatment of TK6 cells brought about efficient cell growth inhibition, G2/M arrest, and apoptosis, as indicated by the results of cytofluorimetric analysis of 5-bromo-2′-deoxyuridine incorporation and DNA content and evaluation of DNA fragmentation. The drug treatment resulted also in the induction of p53 and p21/waf-1 protein expression. In contrast, MT1 cells were highly resistant to the drug and no p53 and p21/waf-1 induction was observed. Importantly, we could show that MT1 cells are not deficient in the p53-dependent apoptosis pathway; treatment with etoposide, a topoisomerase II inhibitor, resulted in p53 and p21/waf-1 protein expression and apoptosis in both cell lines. In conclusion, we demonstrate the existence of a link between a functional mismatch repair system and the trigger of apoptosis in cells exposed to clinically relevant concentrations of temozolomide. The results also suggest that p53 induction in response toO6-guanine methylation involves the mismatch repair system.Keywords
This publication has 26 references indexed in Scilit:
- Strand-specific Mismatch Repair in Mammalian CellsJournal of Biological Chemistry, 1997
- Structure and Function of the p53 Tumor Suppressor Gene: Clues for Rational Cancer Therapeutic StrategiesJNCI Journal of the National Cancer Institute, 1996
- Differential Activation of Target Cellular Promoters by p53 Mutants with Impaired Apoptotic FunctionMolecular and Cellular Biology, 1996
- Cisplatin and Adriamycin Resistance Are Associated with MutLα and Mismatch Repair Deficiency in an Ovarian Tumor Cell LineJournal of Biological Chemistry, 1996
- Competency in mismatch repair prohibits clonal expansion of cancer cells treated with N-methyl-N'-nitro-N-nitrosoguanidine.Journal of Clinical Investigation, 1996
- Mismatch repair and cancerNature, 1994
- An alkylation-tolerant, mutator human cell line is deficient in strand-specific mismatch repair.Proceedings of the National Academy of Sciences, 1993
- Self-destruction and tolerance in resistance of mammalian cells to alkylation damageNucleic Acids Research, 1992
- Phase I trial of temozolomide (CCRG 81045: M&B 39831: NSC 362856)British Journal of Cancer, 1992
- Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.Proceedings of the National Academy of Sciences, 1990